AU2022328282A1 - Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors - Google Patents

Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors Download PDF

Info

Publication number
AU2022328282A1
AU2022328282A1 AU2022328282A AU2022328282A AU2022328282A1 AU 2022328282 A1 AU2022328282 A1 AU 2022328282A1 AU 2022328282 A AU2022328282 A AU 2022328282A AU 2022328282 A AU2022328282 A AU 2022328282A AU 2022328282 A1 AU2022328282 A1 AU 2022328282A1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
deuterium
formula
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022328282A
Other languages
English (en)
Inventor
Adam J. Morgan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Inc
Original Assignee
Sun Pharmaceutical Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Inc filed Critical Sun Pharmaceutical Industries Inc
Publication of AU2022328282A1 publication Critical patent/AU2022328282A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2022328282A 2021-08-12 2022-08-12 Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors Abandoned AU2022328282A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163232538P 2021-08-12 2021-08-12
US63/232,538 2021-08-12
US202163233059P 2021-08-13 2021-08-13
US63/233,059 2021-08-13
PCT/US2022/040190 WO2023018954A1 (en) 2021-08-12 2022-08-12 Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors

Publications (1)

Publication Number Publication Date
AU2022328282A1 true AU2022328282A1 (en) 2024-02-22

Family

ID=83188710

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022328282A Abandoned AU2022328282A1 (en) 2021-08-12 2022-08-12 Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors

Country Status (6)

Country Link
US (1) US20240307401A1 (cg-RX-API-DMAC7.html)
EP (1) EP4384173A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024532765A (cg-RX-API-DMAC7.html)
AU (1) AU2022328282A1 (cg-RX-API-DMAC7.html)
CA (1) CA3228509A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023018954A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116870012A (zh) * 2023-07-26 2023-10-13 北京大学宁波海洋药物研究院 一类甾体硫酸酯化合物在制备jak激酶抑制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CZ20033211A3 (cs) 2001-05-03 2004-09-15 F. Hoffmann-La Roche Ag Farmaceutická léková forma amorfního nelfinavir mesylátu
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
WO2010083283A2 (en) 2009-01-15 2010-07-22 Incyte Corporation Processes for preparing jak inhibitors and related intermediate compounds
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
US10561659B2 (en) 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
CN107759601B (zh) * 2016-08-23 2020-09-11 苏州旺山旺水生物医药有限公司 一种jak抑制剂及其盐的制备方法
BR112019024509A2 (pt) * 2017-05-23 2020-06-23 Theravance Biopharma R&D Ip, Llc Glicuronídeo de pró-fármacos dos inibidores da janus quinase
CN107915738B (zh) 2017-11-14 2019-07-26 海化生命(厦门)科技有限公司 用于合成巴瑞替尼的关键中间体2的制备方法
EP3921318A1 (en) 2019-02-06 2021-12-15 Concert Pharmaceuticals Inc. Process for preparing enantiomerically enriched jak inhibitors
EP4172147A1 (en) 2020-06-29 2023-05-03 Concert Pharmaceuticals Inc. Methods and intermediates for preparing jak inhibitors

Also Published As

Publication number Publication date
US20240307401A1 (en) 2024-09-19
CA3228509A1 (en) 2023-02-16
JP2024532765A (ja) 2024-09-10
WO2023018954A1 (en) 2023-02-16
EP4384173A1 (en) 2024-06-19

Similar Documents

Publication Publication Date Title
US11945816B2 (en) Inhibitors of EGFR and/or HER2 and methods of use
US11814379B2 (en) Cyano quinoline amide compounds as HER2 inhibitors and methods of use
US11969425B2 (en) Inhibitor of indoleamine-2,3-dioxygenase (IDO)
JP7636388B2 (ja) サイクリン依存性キナーゼ７（ｃｄｋ７）の分解誘導剤およびその使用
US20240083934A1 (en) N-acetylgalactosamine (galnac)-derived compounds and oligonucleotides
US8293920B2 (en) Synthesis of enone intermediate
US20110263569A1 (en) Ryanodine channel binders and uses thereof
WO2008144507A2 (en) Spirooxindole inhibitors of aurora kinase
EP4384173A1 (en) Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
CN118159271A (zh) 用jak抑制剂的前药治疗jak抑制应答性病症
US11130764B2 (en) Analogs of vincamine and uses thereof
JP2016155873A (ja) ミグラスタチンおよびその使用
US10273264B2 (en) Cortistatin analogues and syntheses and uses thereof
Monte et al. Methods for controlling the regioselection in the reaction of 3‐amino‐5‐benzylthio‐1, 2, 4‐triazole with acetylacetaldehyde dimethyl acetal
US20240228475A1 (en) Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
WO2025260063A2 (en) Methods of preparing a prmt5 inhibitor
WO2014085791A2 (en) Compositions and uses thereof for treating multiple myeloma